Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 329.99 Mil Enterprise Value: 197.14 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Q2 2023 Oncopeptides AB Earnings Call Transcript

Aug 10, 2023 / 07:00AM GMT
Release Date Price: kr5.87 (+1.82%)
Operator

Welcome to the Oncopeptides Q2 Earnings Call. (Operator Instructions) Now I will hand the conference over to CEO, Sofia Heigis; and CFO, Holger Lembrér. Please go ahead.

Sofia Heigis;publ;CEO
Oncopeptides AB

()-

Hi, everyone and a warm welcome to the Oncopeptides presentation for investors and media of our report for the second quarter. These are the standard disclaimers. My name Sofia Heigis. And on the call, I have our CFO, Holger Lembrér. After my introduction, Holger will give you the financial summary for the second quarter, followed by a commercial update by myself.

While I have been the CFO of the company less than a week, I have been with the company for more than 3 years and focused the last year to lead the commercialization of Pepaxti. I therefore believe that the runway into my new role will be short. I am both humbled and excited about my new role, but I am also full of confidence for 2 reasons. I know the Oncopeptides organization, the competencies, the mindset, the engagement and the drive. I feel

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot